BioNxt Solutions has purchased coating and cutting equipment for its Vektor Pharma TF facility in Germany to enhance its manufacturing capacity. The equipment, which is capable of producing oral dissolvable and transdermal drug formulation products, as well as the company’s oral dissolvable biosensor products, will support the further development and commercialisation of BioNxt’s product pipeline. The move comes as the company seeks to achieve in-house commercial capability in an expedited manner, with a view to developing a versatile production line for pivotal trial materials and final commercial products.
BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that it has purchased state-of-the-art coating and cutting equipment to build out its commercial manufacturing capacity at its Vektor Pharma TF GmbH (“Vektor”) facility in Baden-Württemberg, Germany. The equipment is CE certified and capable of manufacturing the Company’s oral dissolvable (“ODF”) and transdermal (“TDS”) drug formulation products in addition to its ODF biosensor products. This purchase provides for the further development and commercialization of key products in the BioNxt pipeline as well as the capability for strategic contract research and development opportunities.
The German-designed and manufactured coating machine is fully automated with sensor-controlled coating thickness measurement capability. The cutting machine is also German- designed and manufactured and includes fully automated and camera-controlled laser cutting and pick and place robot automation. Both machines are CE certified under European health, safety, and environmental protection standards.
“Building out BioNxt’s commercial manufacturing is a priority for 2023. With BioNxt products advancing toward commercialization and with potential contract development and manufacturing opportunities available, the Company is committed to achieving in-house commercial capability on an expedited basis,” said Hugh Rogers, BioNxt CEO & Director. “We are planning a strategic and versatile production line for pivotal trial materials and final commercial products, both transdermal and oral dissolvable.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
BioNxt’s wholly owned subsidiary, Vektor, is a German narcotics manufacturer, developer, and researcher located in the district of Biberach, Baden-Württemberg, Germany. For over a decade, the company and its team have been leaders in the design, testing and manufacture of innovative, non-invasive drug delivery systems, particularly transdermal patches and sub-lingual strips for the delivery of active pharmaceutical ingredients for the treatment of pain and neurological conditions. According to Precedence Research, the global pharmaceutical drug delivery market size was valued at USD 1,525 billion in 2022 and expected to surpass approximately USD 2,047 billion by 2030.
Source: BioSpace
